Dr. Philip Gribbon


Philip Gribbon is Assistant Head of Department, Fraunhofer IME. After receiving a PhD in Biophysics from Imperial College on Biophysical Properties of Glycosaminoglycans, Philip worked at the University of Manchester using fluorescence photobleaching to track glycan interactions in connective tissue. Moving to industry in 2000, Philip was part of the assay development and screening teams at Pfizer. In 2005, Philip moved to GSK and was involved in the development of label free assay technologies. In 2008, Philip became Chief Scientific Officer of the European ScreeningPort a small molecule screening company working exclusively with academic partners. In 2014, Philip joined the Fraunhofer organization. Philip’s research interests are directed towards maximising the impact of screening methods through the use of assays with greater biologically relevance (eg iPS derived cell lines) and development of biophysical based screening methods based on surface enhanced Raman spectroscopy.

In the INTEGRATE-ETN, Dr. Gribbon is the main supervisor for ESR9. The research project of ESR9 involves identification and optimization of covalent inhibitors of ClpP using in silico and in vitro screening approaches. The project is also responsible for validation of hit compounds in target-based functional assays and assessment of off-target compound activities. (WP3).


This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Sklodowska Curie grant agreement No  642620
European Union